EHR-EMBEDDED OCDT IN BREAST OR GI CANCER
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/3/2019 |
| Start Date: | March 2019 |
| End Date: | March 2022 |
| Contact: | Nadine McCleary, MD, MPH |
| Email: | nj_mccleary@dfci.harvard.edu |
| Phone: | 617-632-6729 |
Nonrandomized Phase II Feasibility Study: Assess the Feasibility and Acceptance of a Compound, EHR-embedded Oral Cancer Directed Therapy (OCDT) Toxicity and Adherence Care Management Program for Patients With Advanced Breast or Gastrointestinal Cancer at Dana-Farber/Harvard Cancer Center
This is research study is for participants with advanced breast or gastrointestinal cancer
who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study
is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity
at home, adherence to treatment and integrate toxicity/adherence reporting.
who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study
is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity
at home, adherence to treatment and integrate toxicity/adherence reporting.
For patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed
Therapy.
- Participants will complete ePRO clinic for all medical oncology scheduled provider
appointments during the study period per standard practice
- Participants between clinic visits, will be asked to complete the oral weekly survey at
home via the mobile or web based patient portal. The survey can be completed on a
computer, tablet or smartphone at home or on a tablet at the time of scheduled visit.
- The first 100 participants to complete the survey will receive a passive care team
alert for responses (per DFHCC policy)
- The second 100 participants to complete the survey will receive an active care team
alert for responses.
Therapy.
- Participants will complete ePRO clinic for all medical oncology scheduled provider
appointments during the study period per standard practice
- Participants between clinic visits, will be asked to complete the oral weekly survey at
home via the mobile or web based patient portal. The survey can be completed on a
computer, tablet or smartphone at home or on a tablet at the time of scheduled visit.
- The first 100 participants to complete the survey will receive a passive care team
alert for responses (per DFHCC policy)
- The second 100 participants to complete the survey will receive an active care team
alert for responses.
Inclusion Criteria:
- Adult age 18 or older
- Male or Female
- Scheduled visit at DF/HCC within the BOC or GCC
- Diagnosis of advanced breast cancer or gastrointestinal cancer
- Prescribed any OCDT within prior 5 days of screening
- English as the primary language (as documented in the EHR, written or spoken, and
patient interpreter needed flag = no)
- Mobile number listed in EHR to allow participation in ePP portion of the study
- Women of any pregnancy status
- Patients diagnosed with an advanced cancer will be eligible to participate in the
study until discontinuation of OCDT or death, whichever occurs first
Exclusion Criteria
- Adults unable to provide verbal consent
- Pediatric patients
- Patients without access to a electronic device (including tablet, computer, aptop or
smartphone)
We found this trial at
1
site
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Nadine McCleary, MD, MPH
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
